Bavarian Nordic to Host First Quarter 2024 Results Conference Call and Webcast
Bavarian Nordic A/S (OMX: BAVA) will announce its 2024 first quarter results on Wednesday, May 8, 2024. The management…
Bavarian Nordic A/S (OMX: BAVA) will announce its 2024 first quarter results on Wednesday, May 8, 2024. The management…
Bavarian Nordic A/S (OMX: BAVA) today announced the award of a contract valued at EUR 65 million to supply its MVA-BN® s…
Bavarian Nordic A/S (OMX: BAVA) announced today that JYNNEOS®, the only FDA-approved mpox vaccine, is now commercially a…
Bavarian Nordic A/S (OMX: BAVA) announced today that the Swiss Agency for Therapeutic Products, Swissmedic, has approved…
Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results for the first nine months of 2023 and busi…
Bavarian Nordic A/S (OMX: BAVA) will announce its 2023 third quarter results on Thursday, November 16, 2023. The manag…
Bavarian Nordic A/S (OMX: BAVA) announced today, that it has been awarded another contract valued at more than EUR 11 mi…
Contract award will support manufacturing of new bulk vaccine to partly replenish the inventory used for the mpox ou…
Interroll is committed to professional communication, associations and continues to focus on key topics such as ESG, dig…
The number of industrial robots operating in factories worldwide continues to rise. To use robots efficiently and maximi…